Huntingtin protein: A new option for fixing the Huntington's disease countdown clock

[1]  Stefan Kochanek,et al.  The cryo-electron microscopy structure of huntingtin , 2018, Nature.

[2]  R. Langen,et al.  The 17-residue-long N terminus in huntingtin controls stepwise aggregation in solution and on membranes via different mechanisms , 2017, The Journal of Biological Chemistry.

[3]  Francesco Albert Bosco Cortese,et al.  RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA , 2017, Translational Neurodegeneration.

[4]  S. Tabrizi,et al.  Therapies targeting DNA and RNA in Huntington's disease , 2017, The Lancet Neurology.

[5]  S. Gustincich,et al.  Huntingtin polyQ Mutation Impairs the 17β-Estradiol/Neuroglobin Pathway Devoted to Neuron Survival , 2017, Molecular Neurobiology.

[6]  J. Oliveira,et al.  Modulation of Molecular Chaperones in Huntington’s Disease and Other Polyglutamine Disorders , 2016, Molecular Neurobiology.

[7]  Shihua Li,et al.  Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes , 2017, The Journal of Neuroscience.

[8]  T. Zapara,et al.  Protein–protein interactions of huntingtin in the hippocampus , 2017, Molecular Biology.

[9]  Ge Zhang,et al.  Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes , 2017, International journal of molecular sciences.

[10]  J. Marsh,et al.  Polyglutamine expansion affects huntingtin conformation in multiple Huntington’s disease models , 2017, Scientific Reports.

[11]  Ansgar B. Siemer,et al.  Formation and Structure of Wild Type Huntingtin Exon-1 Fibrils. , 2017, Biochemistry.

[12]  R. Cole,et al.  Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats. , 2017, Journal of proteome research.

[13]  D. Rubinsztein,et al.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. , 2017, Cold Spring Harbor perspectives in medicine.

[14]  A. Thakur,et al.  Inhibition of polyglutamine aggregation by SIMILAR huntingtin N‐terminal sequences: Prospective molecules for preclinical evaluation in Huntington's disease , 2017, Biopolymers.

[15]  T. Dobránsky,et al.  N-type Ca2+ channels are affected by full-length mutant huntingtin expression in a mouse model of Huntington's disease , 2017, Neurobiology of Aging.

[16]  D. Keating,et al.  Huntingtin-associated protein-1 (HAP1) regulates endocytosis and interacts with multiple trafficking-related proteins. , 2017, Cellular signalling.

[17]  M. Levitt,et al.  Emerging β-Sheet Rich Conformations in Supercompact Huntingtin Exon-1 Mutant Structures. , 2017, Journal of the American Chemical Society.

[18]  K. Ghaedi,et al.  Huntington’s Disease and Mitochondria , 2017, Neurotoxicity Research.

[19]  C. Leumann,et al.  Enzymatic Synthesis of 7',5'-Bicyclo-DNA Oligonucleotides. , 2017, Chemistry, an Asian journal.

[20]  A. Dolga,et al.  Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine core , 2017, Nature Communications.

[21]  C. Isidoro,et al.  Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation , 2017, Neurochemistry International.

[22]  F. Giorgini,et al.  Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity , 2017, bioRxiv.

[23]  A. Pastore,et al.  Mutant Exon1 Huntingtin Aggregation is Regulated by T3 Phosphorylation-Induced Structural Changes and Crosstalk between T3 Phosphorylation and Acetylation at K6. , 2017, Angewandte Chemie.

[24]  B. Luan,et al.  Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment. , 2017, The journal of physical chemistry. B.

[25]  Peter G Wolynes,et al.  Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington’s disease , 2017, Proceedings of the National Academy of Sciences.

[26]  Günter Mayer,et al.  Aptamers as Valuable Molecular Tools in Neurosciences , 2017, The Journal of Neuroscience.

[27]  J. Legleiter,et al.  Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease. , 2017, Biochemistry.

[28]  K. E. Lundin,et al.  CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression , 2017, Nucleic acids research.

[29]  Elise M. Braatz,et al.  Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion , 2017, Journal of Huntington's disease.

[30]  Lucio Frydman,et al.  Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective. , 2017, Journal of the American Chemical Society.

[31]  Martin L. Duennwald,et al.  Polyglutamine toxicity in yeast uncovers phenotypic variations between different fluorescent protein fusions , 2017, Traffic.

[32]  D. Musumeci,et al.  G-quadruplex-based aptamers against protein targets in therapy and diagnostics☆ , 2016, Biochimica et Biophysica Acta (BBA) - General Subjects.

[33]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[34]  R. Veedu,et al.  In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies , 2016, RNA biology.

[35]  T. Arnesen,et al.  The world of protein acetylation. , 2016, Biochimica et biophysica acta.

[36]  N. Gogtay,et al.  Therapeutic nucleic acids: current clinical status , 2016, British journal of clinical pharmacology.

[37]  Xia Zhang,et al.  Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches , 2016, Experimental and therapeutic medicine.

[38]  S. Valentine,et al.  Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding. , 2016, Biophysical journal.

[39]  M. Melone,et al.  The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders , 2016, Medicinal research reviews.

[40]  R. Aebersold,et al.  Huntingtin’s spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function , 2016, eLife.

[41]  N. Mousseau,et al.  Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution. , 2016, Biophysical journal.

[42]  S. Humbert,et al.  The Biology of Huntingtin , 2016, Neuron.

[43]  K. Kar,et al.  Huntingtin exon 1 fibrils feature an interdigitated β-hairpin–based polyglutamine core , 2016, Proceedings of the National Academy of Sciences.

[44]  I. Roy,et al.  Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease. , 2015, Molecular Therapy.

[45]  Sean J. Humphrey,et al.  Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation , 2015, Trends in Endocrinology & Metabolism.

[46]  P. Nielsen,et al.  Allele-Selective Inhibition of Mutant Huntingtin with 2-Thio- and C5- Triazolylphenyl-Deoxythymidine-Modified Antisense Oligonucleotides. , 2015, Nucleic acid therapeutics.

[47]  J. Botas,et al.  Huntingtin proteolysis releases non‐polyQ fragments that cause toxicity through dynamin 1 dysregulation , 2015, The EMBO journal.

[48]  D. Musumeci,et al.  G-Quadruplex Forming Oligonucleotides as Anti-HIV Agents , 2015, Molecules.

[49]  R. Langen,et al.  Solid-State Nuclear Magnetic Resonance on the Static and Dynamic Domains of Huntingtin Exon-1 Fibrils. , 2015, Biochemistry.

[50]  A. Brivanlou,et al.  Discovery of Novel Isoforms of Huntingtin Reveals a New Hominid-Specific Exon , 2015, PloS one.

[51]  D. Ehrnhoefer,et al.  Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice , 2015, Neurobiology of Disease.

[52]  Shaun S. Sanders,et al.  Aberrant palmitoylation in Huntington disease. , 2015, Biochemical Society transactions.

[53]  James R Arndt,et al.  The emerging role of the first 17 amino acids of huntingtin in Huntington’s disease , 2015, Biomolecular concepts.

[54]  David W. Colby,et al.  Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease. , 2015, Human molecular genetics.

[55]  H. Bellen,et al.  Huntingtin Functions as a Scaffold for Selective Macroautophagy , 2015, Nature Cell Biology.

[56]  Praveen Dayalu,et al.  Huntington disease: pathogenesis and treatment. , 2015, Neurologic clinics.

[57]  E. Reits,et al.  Detection of ubiquitinated huntingtin species in intracellular aggregates , 2015, Front. Mol. Neurosci..

[58]  S. Valentine,et al.  Acetylation Regulates the Interaction of Huntingtin with Lipid Membranes: Implications for Huntington Disease , 2015 .

[59]  D. Ehrnhoefer,et al.  A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. , 2015, Human molecular genetics.

[60]  E. Verdin,et al.  50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond , 2014, Nature Reviews Molecular Cell Biology.

[61]  A. Caricasole,et al.  Polyglutamine- and Temperature-Dependent Conformational Rigidity in Mutant Huntingtin Revealed by Immunoassays and Circular Dichroism Spectroscopy , 2014, PloS one.

[62]  R. Fairman,et al.  Role of the coiled-coil structural motif in polyglutamine aggregation. , 2014, Biochemistry.

[63]  R. Fairman,et al.  Effect of helical flanking sequences on the morphology of polyglutamine-containing fibrils. , 2014, Biochemistry.

[64]  K. Kar,et al.  Polyglutamine Amyloid Core Boundaries and Flanking Domain Dynamics in Huntingtin Fragment Fibrils Determined by Solid-State Nuclear Magnetic Resonance , 2014, Biochemistry.

[65]  J. Lucas,et al.  Ubiquitin–proteasome system involvement in Huntington’s disease , 2014, Front. Mol. Neurosci..

[66]  N. Aronin,et al.  Huntingtin‐lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing , 2014, Movement disorders : official journal of the Movement Disorder Society.

[67]  M. Radrizzani,et al.  B01 Development Of Aptamers For The Specific Detection Of The Amino-terminal Region Of The Huntingtin Protein , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[68]  A. Brivanlou,et al.  Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. , 2014, Developmental biology.

[69]  M. Davidson,et al.  Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. , 2014, Human Molecular Genetics.

[70]  R. Wetzel,et al.  Aggregation Behavior of Chemically Synthesized, Full-Length Huntingtin Exon1 , 2014, Biochemistry.

[71]  C. Aisenbrey,et al.  Investigation of membrane penetration depth and interactions of the amino-terminal domain of huntingtin: refined analysis by tryptophan fluorescence measurement , 2014, European Biophysics Journal.

[72]  K. Burke,et al.  Curvature enhances binding and aggregation of huntingtin at lipid membranes. , 2014, Biochemistry.

[73]  M. Mort,et al.  Identification of novel alternative splicing events in the huntingtin gene and assessment of the functional consequences using structural protein homology modelling. , 2014, Journal of molecular biology.

[74]  Chuan-en Wang,et al.  Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A , 2014, Proceedings of the National Academy of Sciences.

[75]  P. Djian,et al.  Monomeric, Oligomeric and Polymeric Proteins in Huntington Disease and Other Diseases of Polyglutamine Expansion , 2014, Brain sciences.

[76]  R. Cole,et al.  Phosphorylation of Mutant Huntingtin at Serine 116 Modulates Neuronal Toxicity , 2014, PloS one.

[77]  Sean D. Mooney,et al.  A Large Scale Huntingtin Protein Interaction Network Implicates Rho GTPase Signaling Pathways in Huntington Disease*♦ , 2014, The Journal of Biological Chemistry.

[78]  Anu Nagarajan,et al.  The effects of flanking sequences in the interaction of polyglutamine peptides with a membrane bilayer. , 2014, The journal of physical chemistry. B.

[79]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[80]  R. Pappu,et al.  Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation , 2013, Proceedings of the National Academy of Sciences.

[81]  D. Housman,et al.  Aberrantly spliced HTT, a new player in Huntington’s disease pathogenesis , 2013, RNA biology.

[82]  M. Hayden,et al.  Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS , 2013, Nucleic acids research.

[83]  B. Bechinger,et al.  Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach. , 2013, Biophysical journal.

[84]  K. Burke,et al.  Huntingtin disrupts lipid bilayers in a polyQ-length dependent manner. , 2013, Biochimica et biophysica acta.

[85]  R. Truant,et al.  Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin , 2013, Proceedings of the National Academy of Sciences.

[86]  Jaclyn R. Gareau,et al.  SUMO-2 and PIAS1 Modulate Insoluble Mutant Huntingtin Protein Accumulation , 2013, Cell reports.

[87]  K. Burke,et al.  The Interaction of Polyglutamine Peptides with Lipid Membranes Is Regulated by Flanking Sequences Associated with Huntingtin* , 2013, The Journal of Biological Chemistry.

[88]  G. Bernardi,et al.  Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease , 2013, Neurobiology of Disease.

[89]  L. Smeeth,et al.  Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[90]  B. Bechinger,et al.  Membrane interactions of the amphipathic amino terminus of huntingtin. , 2013, Biochemistry.

[91]  B. Bechinger,et al.  Membrane Structure and Interactions of the Amphipathic N-Terminus of Huntingtin , 2013 .

[92]  D. Housman,et al.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease , 2013, Proceedings of the National Academy of Sciences.

[93]  M. Diamond,et al.  An N-terminal Nuclear Export Signal Regulates Trafficking and Aggregation of Huntingtin (Htt) Protein Exon 1* , 2013, The Journal of Biological Chemistry.

[94]  R. Truant,et al.  The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal , 2013, Human molecular genetics.

[95]  D. Borchelt,et al.  Analysis of Proteolytic Processes and Enzymatic Activities in the Generation of Huntingtin N-Terminal Fragments in an HEK293 Cell Model , 2012, PloS one.

[96]  Daniela Montesarchio,et al.  Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer. , 2012, Pharmacology & therapeutics.

[97]  Ronald Wetzel,et al.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. , 2012, Journal of molecular biology.

[98]  P. Patterson,et al.  Structural Features and Domain Organization of Huntingtin Fibrils* , 2012, The Journal of Biological Chemistry.

[99]  G. Bates,et al.  Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington’s disease , 2012, PLoS currents.

[100]  S. Horvath,et al.  Network Organization of the Huntingtin Proteomic Interactome in Mammalian Brain , 2012, Neuron.

[101]  Pasi I. Tuunanen,et al.  Caspase-6 Activity in a BACHD Mouse Modulates Steady-State Levels of Mutant Huntingtin Protein But Is Not Necessary for Production of a 586 Amino Acid Proteolytic Fragment , 2012, The Journal of Neuroscience.

[102]  D. Butler,et al.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins , 2012, Progress in Neurobiology.

[103]  Ramon Eritja,et al.  Thrombin binding aptamer, more than a simple aptamer: chemically modified derivatives and biomedical applications. , 2012, Current pharmaceutical design.

[104]  A. Gronenborn,et al.  Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties. , 2012, Biochemistry.

[105]  S. Finkbeiner,et al.  Identification of Novel Potentially Toxic Oligomers Formed in Vitro from Mammalian-derived Expanded huntingtin Exon-1 Protein* , 2012, The Journal of Biological Chemistry.

[106]  Jianning Wei,et al.  Palmitoylation and trafficking of GAD65 are impaired in a cellular model of Huntington's disease. , 2012, The Biochemical journal.

[107]  R. Wetzel,et al.  Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. , 2012, Journal of molecular biology.

[108]  R. Wetzel,et al.  Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting α-helix-rich oligomeric intermediates. , 2012, Journal of molecular biology.

[109]  A. Laio,et al.  Conformations of the Huntingtin N‐term in aqueous solution from atomistic simulations , 2011, FEBS letters.

[110]  B. Shaby,et al.  SUPPLEMENTARY INFORMATION Identifying polyglutamine protein species in situ that best predict neurodegeneration , 2011 .

[111]  Y. Niu,et al.  Improving the stability of aptamers by chemical modification. , 2011, Current medicinal chemistry.

[112]  R. Atwal,et al.  Kinase inhibitors modulate huntingtin cell localization and toxicity. , 2011, Nature chemical biology.

[113]  Jianhua Zhang,et al.  Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons , 2011, Molecular Neurodegeneration.

[114]  R. Wetzel,et al.  The aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils. , 2011, Journal of the American Chemical Society.

[115]  D. Ehrnhoefer,et al.  Small Changes, Big Impact , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[116]  L. Kaltenbach,et al.  Perturbation with Intrabodies Reveals That Calpain Cleavage Is Required for Degradation of Huntingtin Exon 1 , 2011, PloS one.

[117]  K. Kar,et al.  Critical nucleus size for disease-related polyglutamine aggregation is repeat length dependent , 2010, Nature Structural &Molecular Biology.

[118]  L. Raymond,et al.  Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 Activation In Vivo , 2010, The Journal of Neuroscience.

[119]  Eric B. Roesch,et al.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. , 2010, Biochemistry.

[120]  A. Messer,et al.  Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice , 2010, Journal of neuropathology and experimental neurology.

[121]  M. Hayden,et al.  A04 Caspase 6 resistant mutant huntingtin does not rescue the toxic effects of caspase cleavable mutant huntingtin in vivo , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[122]  Yohanns Bellaiche,et al.  Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis , 2010, Neuron.

[123]  M. Sierks,et al.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. , 2010, Protein engineering, design & selection : PEDS.

[124]  Andreas Vitalis,et al.  Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin. , 2010, Journal of molecular biology.

[125]  Leslie M Thompson,et al.  Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo* , 2010, The Journal of Biological Chemistry.

[126]  J. Vesenka,et al.  A stable G‐quartet binds to a huntingtin protein fragment containing expanded polyglutamine tracks , 2010, Journal of neuroscience research.

[127]  Martin Karplus,et al.  PR65, the HEAT-repeat scaffold of phosphatase PP2A, is an elastic connector that links force and catalysis , 2010, Proceedings of the National Academy of Sciences.

[128]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[129]  S. Finkbeiner,et al.  IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome , 2009, The Journal of cell biology.

[130]  S. Finkbeiner,et al.  Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.

[131]  P. Patterson,et al.  Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.

[132]  S. Meredith,et al.  Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect. , 2009, Biophysical journal.

[133]  Judith Frydman,et al.  The Chaperonin TRIC Blocks a Huntingtin Sequence Element that promotes the Conformational Switch to Aggregation , 2009, Nature Structural &Molecular Biology.

[134]  J. Purcell,et al.  Phosphorylation of Threonine 3 , 2009, The Journal of Biological Chemistry.

[135]  B. Nannenga,et al.  Conformational Targeting of Fibrillar Polyglutamine Proteins in Live Cells Escalates Aggregation and Cytotoxicity , 2009, PloS one.

[136]  Xuhui Huang,et al.  The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. , 2009, Journal of molecular biology.

[137]  Qi Zheng,et al.  Hunting for the function of Huntingtin , 2009, Disease Models & Mechanisms.

[138]  R. Cole,et al.  Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells* , 2009, Journal of Biological Chemistry.

[139]  Jeffrey N. Savas,et al.  Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation , 2009, Cell.

[140]  J. Caviston,et al.  Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.

[141]  A. LeBlanc,et al.  Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. , 2009, Biochimica et biophysica acta.

[142]  Erich E. Wanker,et al.  Detection of Alpha-Rod Protein Repeats Using a Neural Network and Application to Huntingtin , 2009, PLoS Comput. Biol..

[143]  Dalaver H. Anjum,et al.  Polyglutamine disruption of the huntingtin exon1 N-terminus triggers a complex aggregation mechanism , 2009, Nature Structural &Molecular Biology.

[144]  P. Patterson,et al.  Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity , 2008, The Journal of Neuroscience.

[145]  M. Hayden,et al.  Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. , 2008, Human molecular genetics.

[146]  Radu Constantinescu,et al.  The relationship between CAG repeat length and clinical progression in Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[147]  Brendan H. Lee,et al.  Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin , 2008, The Journal of cell biology.

[148]  M. Hayden,et al.  Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. , 2008, Brain : a journal of neurology.

[149]  C. Gissi,et al.  Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. , 2008, Molecular biology and evolution.

[150]  Jeremy M. Henley,et al.  Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction , 2007, Nature Reviews Neuroscience.

[151]  R. Atwal,et al.  Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. , 2007, Human molecular genetics.

[152]  R. Stoltenburg,et al.  SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. , 2007, Biomolecular engineering.

[153]  S. Humbert,et al.  Phosphorylation of Huntingtin by Cyclin-Dependent Kinase 5 Is Induced by DNA Damage and Regulates Wild-Type and Mutant Huntingtin Toxicity in Neurons , 2007, The Journal of Neuroscience.

[154]  J. Caviston,et al.  Huntingtin facilitates dynein/dynactin-mediated vesicle transport , 2007, Proceedings of the National Academy of Sciences.

[155]  L. Cardon,et al.  The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset , 2007, Annals of human genetics.

[156]  Yong-Gang Chang,et al.  Structural insights into the specific binding of huntingtin proline-rich region with the SH3 and WW domains. , 2006, Structure.

[157]  Anne Bertolotti,et al.  Critical Role of the Proline-rich Region in Huntingtin for Aggregation and Cytotoxicity in Yeast* , 2006, Journal of Biological Chemistry.

[158]  Eric Kmiec,et al.  Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease , 2006, BMC Neuroscience.

[159]  Michael P. Cusack,et al.  Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry , 2006, Journal of Biological Chemistry.

[160]  Susan Lindquist,et al.  Flanking sequences profoundly alter polyglutamine toxicity in yeast. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[161]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[162]  Wei Li,et al.  Expression and Characterization of Full-length Human Huntingtin, an Elongated HEAT Repeat Protein* , 2006, Journal of Biological Chemistry.

[163]  Lu Gan,et al.  Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.

[164]  P. Lansbury,et al.  Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? , 2006, Quarterly Reviews of Biophysics.

[165]  Ronald Wetzel,et al.  Oligoproline effects on polyglutamine conformation and aggregation. , 2006, Journal of molecular biology.

[166]  Ronald Wetzel,et al.  Polyglutamine aggregation nucleation: Thermodynamics of a highly unfavorable protein folding reaction , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[167]  A. Dürr,et al.  Akt is altered in an animal model of Huntington's disease and in patients , 2005, The European journal of neuroscience.

[168]  G. Peluso,et al.  Huntingtons Disease: New Frontiers for Molecular and Cell Therapy , 2005 .

[169]  David W. Colby,et al.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[170]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[171]  M. Hayden,et al.  Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.

[172]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[173]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[174]  M. MacDonald,et al.  The serum‐ and glucocorticoid‐induced kinase SGK inhibits mutant huntingtin‐induced toxicity by phosphorylating serine 421 of huntingtin , 2004, The European journal of neuroscience.

[175]  Erich E Wanker,et al.  The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.

[176]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[177]  N. Kleckner,et al.  The ATRs, ATMs, and TORs Are Giant HEAT Repeat Proteins , 2003, Cell.

[178]  R. Wetzel,et al.  Mutational analysis of the structural organization of polyglutamine aggregates , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[179]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[180]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[181]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[182]  Pascal Kahlem,et al.  Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. , 2002, Journal of cell science.

[183]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[184]  M. Chesselet,et al.  Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum , 2001, The Journal of Neuroscience.

[185]  A. F. Neuwald,et al.  HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. , 2000, Genome research.

[186]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[187]  Dale E. Bredesen,et al.  Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.

[188]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[189]  Peer Bork,et al.  HEAT repeats in the Huntington's disease protein , 1995, Nature Genetics.

[190]  J T Finch,et al.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[191]  S. Chen,et al.  Intracellular antibodies as a new class of therapeutic molecules for gene therapy. , 1994, Human gene therapy.

[192]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[193]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[194]  P. Muchowski,et al.  N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion. , 2017, Journal of Huntington's disease.

[195]  W. Krzyzosiak,et al.  Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs. , 2016, Acta biochimica Polonica.

[196]  M. Mort,et al.  Huntingtin Exists as Multiple Splice Forms in Human Brain. , 2015, Journal of Huntington's disease.

[197]  K. Hauser,et al.  Length-dependent conformational transitions of polyglutamine repeats as molecular origin of fibril initiation. , 2014, Biophysical chemistry.

[198]  S. Humbert,et al.  Huntingtin: here, there, everywhere! , 2013, Journal of Huntington's disease.

[199]  U. Galderisi,et al.  Mutant huntingtin regulates EGF receptor fate in non-neuronal cells lacking wild-type protein. , 2013, Biochimica et biophysica acta.

[200]  D. Ehrnhoefer,et al.  Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. , 2012, Journal of Huntington's disease.

[201]  D. Krainc.  Huntington's disease: tagged for clearance , 2010, Nature Medicine.

[202]  Z. Qin,et al.  The role of post-translational modifications of huntingtin in the pathogenesis of Huntington’s disease , 2010, Neuroscience Bulletin.

[203]  I. V. Kovtun,et al.  Features of trinucleotide repeat instability in vivo , 2008, Cell Research.

[204]  J. Gusella,et al.  Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine , 2007, Journal of Molecular Neuroscience.

[205]  N. Déglon,et al.  Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421 , 2006, The Journal of Neuroscience.